Background: Protection against hepatitis B disease after immunization is considered as relying on both the persistence of protective serum antibodies and the ability of the immune system to mount an anamnestic response when rechallenged with the hepatitis B virus (HBV). Hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix hexa TM ) has been found to induce comparable seroprotective antibody levels against hepatitis B as monovalent hepatitis B vaccines in the short-term, and this study evaluated the long-term immune memory towards HBV in children aged 4-5 years.
Background: The introduction of oral live attenuated human rotavirus vaccine RIX4414 (Rotarix TM , GSK Bio-logicals) into childhood immunisation schedules can be facilitated by concomitant administration with routine diphtheria-tetanus-whole cell pertussis (DTPw) vaccine combinations. This multicentre trial (104021) assessed the impact of co-administering RIX4414 vaccine on the immune response to primary vaccination with two formulations of DTPw-hepatitis B [DTPw-HBV (Zilbrix TM or Tritanrix TM ); GSK Biologicals].
Methods: Healthy infants 11-17 weeks of age were randomised to receive one of the following vaccination regimens at 3, 4.5 and 6 months of age: RIX4414 vaccine (3 and 4.5 months) + DTPw-HBV (Zilbrix TM or Tritanrix TM ); RIX4414 placebo (3 and 4.5 months) + DTPw-HBV (Zilbrix TM or Tritanrix TM ); separate DTPw (Triple Antigen TM ; CSL) + HBV (Engerix TM -B; GSK Biologicals) vaccines. Oral polio vaccine was administered concomitantly to all children. Blood samples for immunogenicity analysis were obtained before vaccination and one month after the third dose of DTPw vaccine (Month 7). Solicited adverse events were recorded on days 0-7 post-vaccination, unsolicited adverse events on days 0-30 and serious adverse events throughout the entire study.
Results: 308 subjects were enrolled and vaccinated, of whom 302 and 254 were included in the ATP cohorts for safety and immunogenicity, respectively. One month after the third primary vaccination dose, (2.5 months after the second RIX4414 dose), anti-rotavirus seroconversion rates70.0-74.5% were seen in the 2 groups receiving RIX4414. In the groups receiving DTPw-HBV combinations, seroprotection against diphtheria, tetanus, hepatitis B, poliovirus types 1, 2 and 3 and vaccine response to B. pertussis was seen in 100%, 100%, 100%, ≥97.3% and ≥96.2% of subjects, respectively. No significant increase in the incidence of solicited adverse events was observed with coadministration of the RIX4414 vaccine. All vaccine regimens showed similar reactogenicity and safety profile.
Conclusion: Co-administration of neither RIX4414 (Rotarix TM ) nor DTPw-HBV vaccines impacted on the immune response of the other vaccine. Methods: Randomized parallel group assessor-blind trial. Patients (N = 120) were enrolled ≤48 hours since disease onset to receive erythromycin 50 mg/kg/day over 5 days, single-dose azithromycin 20 mg/kg or 30 mg/kg, or no 13th International Congress on Infectious Diseases Abstracts, Poster Presentations e79 antibiotic (no treatment-control) (1:1:1:1). Antibiotics were commenced 8-10 hours after enrollment. Patients were assessed in 24-hour intervals over 6 days.
Results: In the intent-to-treat analysis, Campylobacter eradication was achieved in 20/30 controls and in all antibiotic-treated patients. Incidence of clinical cure during the observed period was 15/30 in the control, 14/30 in the erythromycin, 20/30 in the lower and 25/30 in the higher azithromycin dose group. With adjustment for age, sex, baseline symptom score and disease duration before enrollment, only azithromycin 30 mg/kg was superior to no treatment: incidence ratio (IR) = 1.76 (95% CI 1.11-2.87). It was also superior to erythromycin (IR = 1.80, 97.5% CI 1.13-2.84). Regarding time to clinical cure, only azithromycin 30 mg/kg was superior to no treatment: adjusted hazard ratio (HR = 3.80, 95% CI 1.97-7.32). It was also superior to erythromycin (HR = 4.17, 97.5% CI 1.91-9.09). All antibiotics improved (p < 0.05) symptom score reduction over time, most prominently azithromycin 30 mg/kg, which was also superior to erythromycin (p < 0.001). All treatments were well tolerated.
Conclusion: Single azithromycin 30 mg/kg administration early after disease onset effectively eradicates the pathogen and accelerates clinical cure in childhood Campylobacter enterocolitis. It is clinically superior to an early commenced 5-day erythromycin regimen. 
Children Hospital of Buenos Aires, Buenos Aires, Argentina
Lower back pain is an extremely rare chief complaint in the pediatric population, being more common in adolescents. This finding is usually associated with acute injuries; including infections and malignancy as presumptive diagnoses.
Objective: To consider differential diagnosis in a pediatric patient with lower back pain. To describe a case of osteomyelitis of infrequent location referred to a pediatric tertiary care center in Buenos Aires, Argentina.
Case: 16 yo previously healthy Paraguayan male who presents with progressive lower back pain associated with intermittent fever. He was initially admitted in an outside facility in Paraguay, where initial diagnostic studies (including CBC, UA and CXR) did not reveal abnormal results. He was treated with a third-generation cephalosporin for five days, with resolution of the fever. Back pain was unresponsive to antimicrobial therapy and to NSAID. After being 14 days afebrile patient developed fever again which prompted his referral to our institution.
On admission he presented leukocytosis, increased acute phase reactants and Spine X ray and Spine CT showing a lesion at the L5 level, with decreased height of the vertebral body as well as decreased intervertebral space in between L4 and L5. Chest CT was positive for disseminated nodular lesions predominantly located in the right lung.
Due to concern for oncologic etiology (Ewing's Sarcoma) or infection, further workup was performed, including: --Bone scan (scintigraphy): increased uptake in the right femoral diaphysis, L4 and L5 vertebral bodies --Spine MRI: lesion evident in L5-S1without compromise of the vertebral disc --Bone biopsy (vertebral body).
Pathology report was consistent with Chronic Osteomyelitis with super-imposed acute process without evidence of malignancy. Bone tissue culture and blood cultures were positive for methicillin-resistant Staphylococcus aureus (MRSA).
Patient received 4 weeks of IV antibiotics with clinical, biochemical and radiologic improvement.
Conclusion: Specific lesions account for 85% of children with lower back pain, of which 20% are infectious or oncologic in etiology. doi:10.1016/j.ijid.2008.05.197 
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